Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1115
Peer-review started: October 4, 2022
First decision: December 19, 2022
Revised: January 8, 2023
Accepted: January 20, 2023
Article in press: January 20, 2023
Published online: February 16, 2023
Processing time: 112 Days and 22.7 Hours
Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer that is relatively rare, aggressive, and prone to early metastasis and has a poor prognosis. Currently, there are limited studies on C-SCLC, and there is no uniform standard treatment, especially for extensive C-SCLC, which still faces great challenges. In recent years, the development and progress of immunotherapy have provided more possibilities for the treatment of C-SCLC. We used immunotherapy combined with first-line chemotherapy to treat extensive-stage C-SCLC to explore its antitumor activity and safety.
We report a case of C-SCLC that presented early with adrenal, rib, and mediastinal lymph node metastases. The patient received carboplatin and etoposide with concurrent initiation of envafolimab. After 6 cycles of chemot
Envafolimab combined with carboplatin and etoposide in the treatment of extensive-stage C-SCLC has preliminary antitumor activity and good safety and tolerability.
Core Tip: Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer, which is relatively rare, aggressive, prone to early metastasis, and has a poor prognosis. With the development and progress of immunotherapy, several clinical studies have shown that programmed death ligand-1 combined with chemotherapy can effectively prolong the progression-free survival and median overall survival of patients with extensive stage small cell lung cancer, but its efficacy in C-SCLC is not exact. In this paper, we report a patient with extensive stage C-SCLC who was treated with envafolimab combined with carboplatin and etoposide with preliminary anti-tumor activity, safety and tolerability.